Yunnan Baiyao stock: Nine-month revenue rises 5.2 percent

Published on 11/01/2026 at 01:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yunnan Baiyao stock draws attention after nine-month profit edged higher year over year. Earnings per share rose to CNY 2.70 from CNY 2.68.

Nine-Month Results Point To Steady Growth

Revenue reached CNY 32.257 billion, compared with CNY 30.654 billion a year earlier.
Net income rose to CNY 4.823 billion from CNY 4.777 billion.
Earnings per share increased to CNY 2.70 from CNY 2.68.

Yunnan Baiyao, CNE0000008X7, Illustration mit AI erstellt.

Yunnan Baiyao reported higher revenue and profit for the first nine months of 2026, according to RTTNews. Revenue increased 5.2 percent year over year to CNY 32.257 billion, while net income rose to CNY 4.823 billion from CNY 4.777 billion.

Revenue Growth Outpaced Profit Growth

The earnings release showed earnings per share of CNY 2.70, up from CNY 2.68 in the comparable period. The figures point to continued expansion in the reporting period, although the smaller increase in net income than in revenue indicates that profit growth was more restrained than sales growth.

The nine-month update gives investors a fresh view of operating momentum after the company's first-half revenue reached CNY 21.88 billion, according to the company's topic page on ad-hoc-news.de. The latest figures extend that reporting sequence into the third quarter.

Traditional Medicine And Health Products

Yunnan Baiyao develops traditional Chinese medicines and related health products in China. Its business covers pharmaceuticals, Chinese-medicine resources, health products and pharmaceutical distribution, with products spanning natural medicines, medical devices, personal-care goods and dietary supplements. The company's corporate website describes a business that combines traditional medicine products with consumer-health offerings.

China's pharmaceutical and consumer-health companies remain exposed to domestic demand, healthcare policies and competition across traditional medicine and branded health products. Investors will focus next on whether revenue growth remains broad-based and whether profit growth catches up with sales.